Opiant Pharmaceuticals, Inc.

UEI
KM23KYBML5N8
CAGE
73QL8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
opiant.com
Employees
1K-5K
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of an intranasal, long duration opioid antagonist to treat opioid overdose U01DA046093 National Institute on Drug Abuse (NIH) $10,988,735

Quick answers

Is Opiant Pharmaceuticals, Inc. registered in SAM.gov?

Opiant Pharmaceuticals, Inc.'s SAM.gov registration expired on February 12, 2023.

What is Opiant Pharmaceuticals, Inc.'s most recent federal award?

Opiant Pharmaceuticals, Inc.'s most recent federal grant award is Development of an intranasal, long duration opioid antagonist to treat opioid overdose (U01DA046093), from National Institute on Drug Abuse (NIH), on May 1, 2018.

On GovTribe

See Opiant Pharmaceuticals, Inc.'s full federal record

  • IDV awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login